Skip to content
As AbbVie’s Humira faces copycat biologics, the biggest beneficiaries will be the middlemen negotiating and dispensing the drugs such as Cigna and CVS.
Tags: abbv , AbbVie , amgen , AMGN , biology , Biopharmaceuticals , biosimilar drugs , Biotechnology , CI , Cigna , corporate , Corporate/Industrial News , CVS , CVS Health , drug stores , financial Services , general News , generic , Generic/Biosimilar Drugs , Health , health/medical insurance , Healthcare , Healthcare/Life Sciences , heard on the street , Heather Cianfrocco , Humanities , industrial news , industrial property rights , Insurance , Intellectual Property Rights , life sciences , medical insurance , non-life insurance , Patents , pharmaceuticals , pharmacies , Pharmacies/Drug Stores , political , political/general news , retail , retail Wholesale , sciences , Sciences/Humanities , specialty retailing , SYND , TEVA , Teva Pharmaceutical , Teva Pharmaceutical Industries , TEVA.TV , UNH , UnitedHealth Group , wholesale , WSJ-Pro-WSJ.com
Post navigation